RT Journal Article
SR Electronic
T1 Identification of SARS-CoV-2-specific immune alterations in acutely ill patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.21.20248642
DO 10.1101/2020.12.21.20248642
A1 Rébillard, Rose-Marie
A1 Charabati, Marc
A1 Grasmuck, Camille
A1 Filali-Mouhim, Abdelali
A1 Tastet, Olivier
A1 Brassard, Nathalie
A1 Daigneault, Audrey
A1 Bourbonnière, Lyne
A1 Balthazard, Renaud
A1 Moratalla, Ana Carmena
A1 Solorio, Yves Carpentier
A1 Farzam-kia, Negar
A1 Fournier, Antoine Philippe
A1 Gowing, Elizabeth
A1 Jamann, Hélène
A1 Lemaître, Florent
A1 Mamane, Victoria Hannah
A1 Thai, Karine
A1 Cailhier, Jean-François
A1 Chomont, Nicolas
A1 Finzi, Andrés
A1 Chassé, Michaël
A1 Durand, Madeleine
A1 Arbour, Nathalie
A1 Kaufmann, Daniel E.
A1 Prat, Alexandre
A1 Larochelle, Catherine
YR 2020
UL http://medrxiv.org/content/early/2020/12/22/2020.12.21.20248642.abstract
AB Dysregulated immune profiles have been described in symptomatic SARS-CoV-2-infected patients. Whether the reported immune alterations are specific to SARS-CoV-2 infection or also triggered by other acute illnesses remains unclear. We performed flow cytometry analysis on fresh peripheral blood from a consecutive cohort of i) patients hospitalized with acute SARS-CoV-2 infection; ii) patients of comparable age/sex hospitalized for other acute disease (SARS-CoV-2 negative); and iii) healthy controls. Using both data-driven and hypothesis-driven analyses, we found several dysregulations in immune cell subsets (e.g. decreased proportion of T cells) that are similarly associated with acute SARS-CoV-2 infection and non-COVID-19 related acute illnesses. In contrast, we identified specific differences in myeloid and lymphocyte subsets that are associated with SARS-CoV-2 status (e.g. elevated proportion of ICAM-1+ mature/activated neutrophils, ALCAM+ monocytes, and CD38+CD8+ T cells). A subset of SARS-CoV-2-specific immune alterations correlated with disease severity, disease outcome at 30 days and mortality. Our data provides novel understanding of the immune dysregulation that are specifically associated with SARS-CoV-2 infection among acute care hospitalized patients. Our study lays the foundation for the development of specific biomarkers to stratify SARS-CoV-2+ patients at risk of unfavorable outcome and uncover novel candidate molecules to investigate from a therapeutic perspective.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by a grant from the CRCHUM foundation and by grant VR2-173203 from the Canada s COVID-19 Immunity Task Force (CITF), in collaboration with the Canadian Institutes of Health Research (CIHR). The Biobanque Quebecoise de la COVID-19 (BQC-19) is supported by the Fonds de recherche Quebec-Sante (FRQS), Genome Quebec and the Public Health Agency of Canada. D.E.K is a FRQS Merit Research Scholar. N.C., M.D. and C.L. receive a salary award from the FRQS. A.Finzi. and A.P. hold a Canada Research Chair. We gratefully acknowledge Dominique Gauchat and Philippe St-Onge from the flow cytometry platform from CRCHUM for excellent technical guidance and support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the CRCHUM ethic committee in accordance with the Declaration of Helsinki (IRB protocols 19.387 and 19.389). Informed consent was obtained for each patientAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesn/a